ACR-ARHP Roundup

 Infinity Pharmaceuticals Inc., of Cambridge, Mass., released new data from its completed Phase I study of IPI-145, the company's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.